No Data
No Data
No Data
No Data
No Data
Investors Aren't Buying Jazz Pharmaceuticals Plc's (NASDAQ:JAZZ) Revenues
You may think that with a price-to-sales (or "P/S") ratio of 1.8x Jazz Pharmaceuticals plc (NASDAQ:JAZZ) is a stock worth checking out, seeing as almost half of all the Pharmaceuticals companies in th
Simply Wall StApr 24 10:39 ET
Jazz Pharmaceuticals Employees Wear Purple To Support Epilepsy Awareness and Community
Originally published by Jazz PharmaceuticalsNORTHAMPTON, MA / ACCESSWIRE / April 23, 2024 / Purple Day spotlights epilepsy and the challenges that people face when living with the condition.Jazz wants
AccesswireApr 23 11:15 ET
Jazz Pharmaceuticals (JAZZ) Gets a Buy From Barclays
TipRanksApr 23 05:59 ET
Express News | Jazz Pharmaceuticals PLC : Needham Raises Target Price to $222 From $220: Needham Raises Target Price to $222 From $220
Moomoo 24/7Apr 19 05:36 ET
Express News | Jazz Pharmaceuticals to Report 2024 First Quarter Financial Results on May 1, 2024
Moomoo 24/7Apr 17 16:15 ET
HER2+ Market to Accelerate Substantially by 2034, Predicts DelveInsight | Key Companies - Zymeworks, Jazz Pharmaceuticals, Ambrx, AnBogen Therapeutics, Enliven Therapeutics, Roche
New York, USA, April 17, 2024 (GLOBE NEWSWIRE) -- HER2+ Market to Accelerate Substantially by 2034, Predicts DelveInsight | Key Companies - Zymeworks, Jazz Pharmaceuticals, Ambrx, AnBogen Therapeutics, Enliven
GlobeNewswireApr 17 13:00 ET
No Data
No Data